Evidence map›Paper›PMID 39781469›Full record

ArticleInternational journal of biological sciences2025

Downregulated CCND3 Is a Key Event Driving Lung Adenocarcinoma Metastasis during Acquired Cisplatin Resistance.

Yun Su, Yuting Ma, Yubing Wang, Ping Xu, Miaoling Guo, Haolin Cao, Jianyang Xin, Xi Wu, Xiaoyan Liu, Shan Chen and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in International journal of biological sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance.International journal of biological sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Yun SuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Yuting MaGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Yubing WangDepartment of Cardiothoracic Vascular Surgery, Guangzhou Eighth People's Hospital, Guangzhou Medical University, Guangzhou 510440, China.
Ping XuDepartment of Pulmonary and Critical Care Medicine Peking University Shenzhen Hospital, Shenzhen 518036, China.
Miaoling GuoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Haolin CaoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Jianyang XinGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Xi WuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Xiaoyan LiuGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Shan ChenGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Xingyu TaoGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Huiling YangSchool of Pharmacy, Guangdong Medical University, Dongguan 523808, China.
Chao ChengDepartment of Otolaryngology, Shenzhen Longgang Otolaryngology Hospital, Shenzhen 518172, China.
Rongquan HuangGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Rongshuai PanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Yuexin PanGuangzhou Municipal and Guangdong Provincial Key Laboratory of Protein Modification and Degradation, Guangzhou Medical University, Guangzhou 511436, China.
Beixian ZhouThe People's Hospital of Gaozhou, Gaozhou 525200, China.
Weiyi FangThe People's Hospital of Gaozhou, Gaozhou 525200, China.
Zhen LiuThe People's Hospital of Gaozhou, Gaozhou 525200, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cyclin D3 (CCND3), a member of the cyclin D family, is known to promote cell cycle transition. In this study, we found that CCND3 was downregulated in cisplatin-resistant (

Indexed as

Adenocarcinoma of LungCisplatinCyclin D3Drug Resistance, NeoplasmEpithelial-Mesenchymal TransitionLung NeoplasmsAdenocarcinomaAnimalsAntineoplastic AgentsCell Line, TumorDown-RegulationFemaleHumansMiceMice, NudeAntineoplastic AgentsCCND3 protein, humanCisplatinCyclin D3acquired DDP chemoresistanceCCND3lung adenocarcinomametastasisvimentin

Identifiers

PMID39781469
PMCPMC11705650

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.